key: cord-0324899-dkvhbcfo
authors: Wijesinghe, Ashan; Kumari, Sarika; Booth, Valerie
title: Conjugates for use in peptide therapeutics: a systematic review and meta-analysis
date: 2021-08-05
journal: bioRxiv
DOI: 10.1101/2021.08.05.455324
sha: ac84b452603b3e626a07d8e46e66a98ea49cf83d
doc_id: 324899
cord_uid: dkvhbcfo

While peptides can be excellent therapeutics for several conditions, their limited in vivo half-lives have been a major bottleneck in the development of therapeutic peptides. Conjugating the peptide to an inert chemical moiety is a strategy that has repeatedly proven to be successful in extending the half-life of some therapeutics. This systematic review and meta-analysis was conducted to examine the available literature and assess it in an unbiased manner to determine which conjugates, both biological and synthetic, provide the greatest increase in therapeutic peptide half-life. Systematic searches run on PubMed, Scopus and SciFinder databases resulted in 845 studies pertaining to the topic, 16 of these were included in this review after assessment against pre-specified inclusion criteria registered on PROSPERO (#CRD42020222579). The most common reasons for exclusion were non-IV administration and large peptide size. Of the 16 studies that were included, a diverse suite of conjugates that increased half-life from 0.1 h to 33.57 h was identified. Amongst these peptides, the largest increase in half-life was seen when conjugated with glycosaminoglycans. A meta-analysis of studies that contained fatty acid conjugates indicated that acylation contributed to a statistically significant extension of half-life. Additionally, another meta-analysis followed by a sensitivity analysis suggested that conjugation with specifically engineered recombinant peptides might contribute to a more efficient extension of peptide half-life as compared to PEGylation. Moreover, we confirmed that while polyethylene glycol is a good synthetic conjugate, its chain length likely has an impact on its effectiveness in extending half-life. Furthermore, we found that most animal studies do not include as much detail when reporting findings as compared to human studies. Inclusion of additional experimental detail on aspects such as independent assessment and randomization may be an easily accomplished strategy to drive more conjugated peptides towards clinical studies.

92 cleared by the kidneys due to their attraction to the negatively charged basement membrane of 93 renal tubules (14) . Proteolysis, on the other hand, can occur both within organs and in the 94 bloodstream (13). A recurrent mechanism used to avoid extracellular proteases is to identify and 95 alter their target site in therapeutic peptides (3). This is commonly done by incorporating D-96 amino acids, which are not susceptible to degradation by endogenous proteases, into these target 97 sites (7). Manipulating peptide size and charge can, therefore, aid in evading renal clearance 98 while stabilizing the peptide structure can help evade extracellular proteolysis. 99 100

Bypassing proteolysis in the liver depends on the peptide's fate following receptor-101 mediated uptake. Peptides that enter hepatocytes in this manner are contained within endosomes 102 where they undergo lysosomal degradation (15). Certain proteins and peptides are, however, 103 rescued by receptor-mediated recycling that sorts these moieties away from the endosome and 104 returns them to the cell surface to continue in circulation. Studies have shown that attaching 105 peptides to moieties that are capable of evading lysosomal degradation in this manner results in 106 lengthened plasma half-life (12). There are, therefore, a number of variables to consider when 107 exploring how to extend peptide half-life in the body. 108 109 Conjugation and its benefits 110 111

Peptide conjugation is a broad approach that encompasses the attachment of chemical 112 moieties to peptides for several reasons including to improve their drug and diagnostic 113 properties. Conjugates used in peptide therapeutics can either be nonbiological molecules like 114 polyethylene glycol (PEG) or biological molecules such as lipids, sugars, and proteins 115 (1,3,7,9,10,13). PEG is one of the most prominent nonbiological conjugates used and has been 116 studied extensively. There are currently about 15 FDA approved PEGylated peptide drugs in the 117 market (3). That said, PEG is not metabolised nor excreted as efficiently as biological molecules 118 are. Therefore, immune reactions and renal effects have been observed due to the toxic 119 accumulation of PEG metabolites (9,16). Consequently, recent research has been exploring 120 alternatives to PEG as a conjugate. With the advancement of recombinant protein production 121 technologies, recombinant peptides too have been incorporated into the range of moieties 122 conjugated to peptide drugs. Unlike with PEG, these conjugates follow the same metabolism and 123 elimination routes as do their therapeutic and endogenous counterparts making them much suited 124 for peptide therapeutics. Another significant area of research includes the study of peptides 125 attached to natural protein domains with inherent bioactivity such as human serum albumin 126 (HSA) and transferrin proteins. In general, studying the pharmacokinetics, or the movement and 127 eventual fate of the conjugates within the body, is of primary interest as it reflects how well the 128 peptides will fare in terms of plasma clearance (14).

In the search for conjugates with favourable characteristics, researchers have observed 131 that attaching moieties capable of increasing the peptide's size and/or altering its charge has 132 potential to successfully extend plasma half-life. Attaching a conjugate that is relatively large 133 like PEG can increase the MW of the peptide by 2 -40 kDa allowing it to evade kidney filtration 134 (7). Similarly, attaching a conjugate that is negatively charged helps avoids renal clearance as 135 detailed in the previous section (13). This does, however, raise concerns about how the peptide-136 conjugate complex's interactions with the targeted substrate might change if the overall charge is 137 altered. Conjugation can also prevent hepatic metabolism of peptides when the conjugate can 138 return the peptide to the hepatic cell surface due to intrinsic bioactivity as demonstrated by HSA 139 and certain antibodies (15). Moreover, many natural protein domains used for this purpose are 140 large enough in size to allow conjugated peptides to evade renal clearance (15). Research has 141 also shown that HSA can function as a carrier for other molecules. This means that conjugating 142 peptides to HSA-binding molecules like lipids can effectively convey the same properties as 143 directly binding to HSA (12,13,15).

Additionally, it has been observed that extracellular enzymatic degradation too can be 146 minimized by conjugation (3). Since endogenous proteases are liable to act on unstructured 147 regions of peptides, conjugates that stabilize the structure of the therapeutic peptide can help 148 escape enzymatic degradation (3,11). Further, addition of conjugates can confer a steric shielding 149 effect against proteases and peptidases (3). Glycosylation and encapsulation of the therapeutic 150 peptide are a few such forms of conjugation that are known to confer protection from 151 extracellular proteases (13). On the whole, it is apparent that conjugation can be successful in 152 prolonging the half-life of therapeutic peptides in the bloodstream. 153 154 The purpose of this systematic review and meta-analysis

Peptides have the potential to become successful therapeutics if the challenge of 157 prolonging their half-life is met. With conjugation being identified as an effective strategy in 158 extending plasma half-life, studies investigating potential conjugates have become more 159 prominent in the past several years. Studying conjugated peptide behaviour also provides insight 160 for drug producers to design and synthesize effective, long-lasting, and less-toxic therapeutic 161 interventions. In just the past decade, 30% of the peptide drugs entering the clinical development 162 stage were conjugated and 40% of these targeted G-protein coupled receptors as molecular 163 targets (2). Alongside conjugation, scientists are also looking at peptide backbone modification, 164 and tertiary and quaternary structure modification (13). However, for this systematic review, we 165 were interested in the data surrounding conjugation as it is by far the least expensive and least 166 complicated strategy employed to extend the half-life of peptides. Furthermore, since there have 167 been large technological advances in the production of peptides by both recombinant expression 168 and chemical synthesis recently, we chose to limit the study to just the last five years.

The main purpose of this systematic review and meta-analysis is to compare the various 171 non-specific conjugates in terms of their contribution to the half-life of therapeutic peptides in 172 the bloodstream as observed in animal studies. With all the above considerations in mind, we 173 aimed to answer the question "within the last 5 years, which non-specific conjugates for 174 therapeutic peptides has led to the greatest peptide half-life in the bloodstream of 175 animals?" In attempting to answer this question in our research, we are hopeful that this 176 systematic review and meta-analysis would contribute to expediting therapeutic design and 177 testing processes, so that more conjugated peptides may be approved as therapeutics in the near 178 future. 179 180 Methods

The methodology detailed here and the eligibility criteria pertinent to this systematic 183 review and meta-analysis were decided upon in advance and documented in the International When screening the studies captured in our search, we ensured that the studies chosen 213 met the pre-specified eligibility criteria ( Table 2 ). All the studies chosen presented plasma half-214 life data in the form of a table or figure. The peptides studied were no larger than insulin in size 215 (5.8 kDa) and were intravenously (IV) administered. This ensured that the data would not be 216 skewed by peptides that were inherently able to avoid plasma clearance due to larger size. 217 Similarly, peptides that were administered via non-intravenous routes, like subcutaneous (SC) or 218 intraperitoneal (IP) injections, were excluded as these routes involve the slow release of 219 therapeutic into the bloodstream, thereby increasing the effective half-life of the peptide (18).

220 Peptides with minor modifications like N & C terminal capping, or modifications required to 221 cyclize peptides were included. Peptides that were modified to the extent where the molar mass 222 of non-peptide moieties approached or exceeded the molar mass of peptide moieties, as in the 223 case of daptomycin, were excluded. Peptides that were composed of D-amino acids were 224 excluded as they can avoid enzymatic degradation via endogenous proteases and peptidases, 225 thereby inherently increasing plasma half-life. 226 227 Table 2 : Eligibility criteria upon which studies were chosen for the Systematic Review

Exclusion Criteria Must be peer-reviewed primary literature.

Must not be a case report, abstract, review, note or conference letter, book chapter or patent Must be a therapeutic peptide

Must not be a non-therapeutic peptide Must be intravenously administered

Must not be non-intravenously administered Must study healthy animals

Must not use diseased animals Must have data on half-life

Must not study a vaccine-related conjugate Must consist of L-amino acids

Must not consist of D-amino acids Must be smaller than insulin in size (5.8 kDa)

Must not be larger than insulin (5.8 kDa) Must be a non-specific, biologically inert conjugate

Must not be a targeted, or specific conjugate May contain minor modifications

Must not be overly modified Must be an English language publication

Must not be a non-English language publication Must have been published between 1 st Sept 2015 and 1 st Sept 2020

Must not have been published prior to 1 st Sept 2015 or after 1 st Sept 2020 228 229

The conjugates included were not restricted in terms of size or molecular class, but 230 conjugates that specifically targeted a specific cell or tissue type in general were excluded. 231 However, there were some conjugates that were on the border of specific vs. non-specific, 232 namely, high-density lipoproteins (HDL) and HSA. We chose to include these moieties as they 233 are transport molecules with targets found abundantly throughout the body, and thus quite 234 different in character compared to truly specific conjugates like target-specific antibodies. HDL 235 participates in reverse-cholesterol transport, a process in which excess peripheral cholesterol is 236 picked up and delivered to the liver (19). HDL-conjugated drugs, therefore, interact with a vast 237 variety of tissues in the periphery before reaching the liver. As such, HDL is considered a 238 suitable conjugate for therapeutic peptides whose target/s may be encountered prior to 239 metabolism in the liver (20). HSA, too, functions similarly in that it transports hormones, 240 vitamins, enzymes, etc. throughout the body. Additionally, HSA-conjugation increases solubility 241 in aqueous media and helps avoid renal clearance (15).

Lastly, we also ensured that only peer-reviewed primary literature was included in this 244 review, thus excluding case reports, abstracts, reviews, conference notes, and patents. The The citations captured by the systematic searches were imported into Covidence, a 254 systematic review management software (21). Covidence automatically detects and removes 255 duplicates upon importation. The duplicate citations excluded at this stage were manually 256 reviewed to ensure they were true duplicates. The rest of the studies were screened in two stages 257 to ensure they fit the eligibility criteria precisely.

In the first stage of screening, only the titles and abstracts were examined with respect to 260 the pre-specified eligibility criteria (Table 2) . Screening was conducted independently by two out 261 of three reviewers, with papers randomly assigned to each reviewer. Each study required two 262 votes to move further: two 'yes' votes to proceed to the next stage, or two 'no' votes to be 263 eliminated. Any conflicts were overruled by a third reviewer's vote or, alternately, consensus 264 was reached by discussion among reviewers. If the title and abstract did not contain adequate 265 details, or if the reviewers were unsure of its eligibility, the study was voted 'yes' and moved on 266 to the next stage of screening. The second stage of screening involved assessing the full text of 267 the articles against the eligibility criteria (Table 2 ). This process too was conducted 268 independently by two reviewers. The third reviewer cast the deciding vote to resolve any 269 disagreements between reviewers. 

Since this review includes many different peptides, doses, animal models, and sample 299 sizes, the true effect size varied from study to study. The random effects model accommodated 300 these differences when determining the combined weighted effect and total variability (24). This 301 model accounts for both intra-study and inter-study variance, where the intra-study variance is 302 calculated using the Tau-squared (τ 2 ) statistic and inter-study variance is adapted from the 303 individual studies (23-25). Assigning weights to studies ensures that more emphasis is placed on 304 studies that carry more information. Therefore, studies with a sample size of 5, for instance, are 305 given more weight than those with only 3 subjects (25). We chose to weight the studies by the 306 inverse of the sum of intra-and inter-study variance, a value that is derived based on corrected 307 sample size and standard deviations (23). This approach is similar to assigning weightings 308 proportional to sample size but is more nuanced in that it minimizes the variance of the 309 combined effect (24). Additionally, we also tested for heterogeneity using the Higgins et al. (26) 310 I 2 model. This statistic is a ratio of intra-study variance to inter-study variance that highlights any 311 important differences (if present) between the studies that may influence the outcome (26). 312 Lastly, a z-test was conducted to determine the statistical significance of the overall effects (24). 313 The statistics involved in the random effects model including combined effect sizes, total 314 variance, heterogeneity, and the z-test were calculated using equations 11.2, 11.3, 12.2 and 12.5 315 -12.14 adapted from Borenstein et al. (24) . 316 317 Sensitivity analysis 318 319

A sensitivity analysis was used to assess each study's contribution to the heterogeneity of 320 the combined effect size (27). To do so, the combined effect size was recalculated while 321 excluding individual studies in the meta-analysis. Any deviation from the overall combined 322 estimate indicated the extent to which the study excluded contributed to the heterogeneity 323 observed, which was used to make inferences about the peptide and conjugate involved (27).

A risk of bias (RoB) analysis was conducted for each study in an anonymized 328 standardized manner by two reviewers. RoB analyses attempt to identify any systematic errors in 329 the methodology of a study with the potential to have affected the results (28). The Systematic 330 Review Centre for Laboratory Animal Experimentation (SYRCLE) RoB tool was used to assess 331 the risk of bias and reporting quality of the studies in our review (29). RoB was assessed across 332 nine domains using detailed signalling questions that were adapted from the Hooijmans et al. 333 (29) guide. For entry 2: Selection bias -Baseline characteristics, it was decided that comparable 334 baseline characteristics include age, sex, and health of the animals. The systematic search conducted to address the research question regarding which 339 conjugate led to the greatest peptide half-life in the bloodstream of animals yielded a total of 845 340 studies: PubMed = 631, Scopus = 82 & SciFinder = 132 (Fig 1) . To ensure that only data of high 341 quality were included in the SRMA, 'grey literature' or research not disseminated through peer-342 reviewed academic journals, were excluded (30). The peer-reviewed, primary literature captured 343 in the individual searches were imported to Covidence which automatically removed duplicates 344 (21). Of the 733 records left to screen, a further 561 records were excluded during the Title and 345 Abstract screening stage as they did not fit the pre-specified inclusion criteria ( Table 2 ). The full 346 texts of the remaining 172 records were then screened to identify 16 studies which matched the 347 selection criteria. The 156 studies excluded at the full text screening stage were sorted into 348 exclusion reasons depicted in Fig. 1 . It was common for the studies to be excluded for multiple 349 reasons; however, Covidence only keeps track of one per study. A few common reasons for 350 exclusion were the large size of the therapeutic peptide that exceeded the cut-off (Table 2) and 351 administration via SC or IP routes rather than IV. Of the 16 studies included in the review, only 5 352 studies were eligible for the application of meta-statistics. This is because performing a meta-353 analysis requires well-defined, experimentally determined controls as well as a measure of 354 standard deviations, which were not available in the remainder of the studies. Table S2 ), while the studies that included comparable 364 controls were further analysed as detailed in the next section. Some of the peptides captured in 365 the group of 16 were well-studied native peptides like insulin and glucagon-like peptide 1 (GLP-366 1) (32-36). Others were novel, heterologous peptides like PN-2921, an interleukin-6 binding 367 peptide derived from a helix-loop-helix scaffold identified through phage display (37). The most 368 abundant, however, were peptide analogues of native peptides such as 22A, a mimetic of 369 apolipoprotein A optimized for conjugation, and Hirulog, a hirudin mimetic (38-40).

Along with the wide range of peptides, a diverse suite of conjugate moieties was 372 encountered in the 16 studies included (Supplementary Table S2 ). Thirty five percent of these 373 studies used PEG or a modified version of PEG as a conjugate, while another 41% of the studies 374 used lipids including fatty acids, cholesterol, and phospholipids, either on their own or 375 conjugated to PEG. While PEG still makes up a significant portion of the conjugates used, seeing 376 more variety is a promising observation since PEG is known to induce immunogenic responses, The animal models used in the studies comprised of varying strains of mice (BALB, ICR, 387 and CD-1), rats (SD, Wistar), and monkeys (Supplementary Table S2 ). In most of the studies, the 388 sex of the animals was specified, with many being male animals. Hence, caution must be taken 389 when extrapolating results from a unisexual sample since the affects may not always be the same 390 in the opposite sex (42). The preferred methods for measuring the amount of peptide present in 391 the bloodstream, and hence the half-lives, were enzyme-linked immunosorbent assays (ELISA) 392 or some form of liquid chromatography-mass spectrometry (LC-MS). 393 394 Comparison of effect sizes 395 396

In comparing the absolute mean difference (effect size) of half-lives of the conjugated 397 peptides to those of the control groups (unconjugated), it is evident that conjugation was 398 generally successful in increasing the plasma half-life of the therapeutics (Table 3) . A range of 399 half-lives from as short as 6 minutes to as long as nearly a day and a half were reported, with the 400 majority of the conjugated peptides exhibiting a half-life extension of several hours. In regards to 401 the control values needed to calculate the effect size for conjugation, four situations were 402 encountered: 1) some studies presented experimentally determined control half-lives which were 403 used in calculating the effect size; 2) other studies did not include experimental controls, but 404 compared their peptide half-lives to control values available in the literature, which we emulated 405 (indicated by a dagger ( †) superscript in Table 3) ; 3) a third group of studies did not include any 406 comparable half-lives, yet, when possible, we calculated their effect sizes by comparing against 407 control values from other papers captured within our systematic review which studied the same 408 peptide (indicated by a double dagger ( ‡) superscript in Table 3 ); 4) lastly, studies that could use 409 neither of these options were excluded entirely from Table 3 . It seems likely that some studies 410 did not include experimentally determined controls because the short half-life of unconjugated 411 peptides was difficult to measure. 412 413 Table 3 : Reported experimental half-lives compared as % increase and absolute mean differences. 452 548 peptide that was engineered specifically for the therapeutic peptide substantially increased the 549 plasma half-life of the therapeutic. Additionally, in comparing fatty acid groups as conjugates 550 (Fig 3b) , a statistically significant combined effect size was observed, indicating that half-life 551 increased when the peptide is acylated. This supports our observation that fatty acids are 552 effective conjugates in increasing plasma half-life. However, it is important to bear in mind that 553 the peptide itself and how it interacts with its surroundings also plays a role in its plasma half-554 life.

When surveying the studies involved in this SRMA, we noticed several details that were 557 not consistent with the expectations for robust pre-clinical trials detailed by SYRCLE. The 558 absence of control data might be seen as one such noteworthy limitation of the studies included. 559 Having a control treatment in the same experiment is crucial as it allows for unbiased 560 comparisons. Some therapeutic peptides may, however, have half-lives that are so short that 561 measuring the half-life of the unconjugated peptide within the time intervals used for the 562 conjugated form may be challenging. One way to work around this issue may be to include time 563 points with shorter intervals immediately after administration. This could possibly capture the 564 half-life of the rapidly eliminated unconjugated peptide alongside that of the conjugated form. 565 Furthermore, the animal model used in most of the studies involved only male animals. This may 566 create issues in extrapolating results to the entire population of animals and subsequently 567 humans. Newer guidelines suggest using a mix of sexes in the experimental group to identify any 568 important differences in how drugs might affect the different sexes (42). Knowing these 569 differences provides insight on how the drug might ultimately affect humans. A large number of 570 the studies included in the review were also assigned an 'unsure' RoB grading in many domains 571 including sequence generation, allocation concealment, random housing, performance bias, and 572 random outcome assessment (Fig 5) . This indicates that there was not enough detail reported to 573 make a fair RoB assessment in that particular domain. Including more details when reporting 574 could increase these drugs' likelihood of proceeding into clinical testing. Conversely, a lack of 575 reported details could lead to issues with reproducibility and translatability preventing further 576 development of the therapeutic. This translational gap between basic science discoveries and 577 clinical drug development has come to be known as the 'valley of death' in drug development 578 (49). Many of these highlighted limitations could nonetheless be avoided by establishing and 579 adhering to comprehensive animal study reporting guidelines as is typical of human trials. 580 581

Overall, this systematic review highlighted the large variety of conjugates being studied 582 for use in therapeutic peptides. Additionally, it brought to light a few factors that may contribute 583 to the translational gap in the field of peptide therapeutics. While there is no doubt that peptides 584 will proceed to hold an important place in pharmaceuticals and healthcare, we are hopeful that 585 future translational research will expedite the process of incorporating these peptide therapeutics 586 into general use against a plethora of diseases. 587 588 Acknowledgements 589 590

Special thanks to Kristen Romme and Erin Alcock from the Memorial University 591 Libraries for their invaluable contribution in tuning up our search strategy, the backbone of this 592 research. 593

Prospective Register of Systematic Reviews (PROSPERO) (Registration # CRD42020222579

Note: the term 'biologically inert' used to describe the conjugates being 186 studied was switched out for 'non-specific' as per the reasoning outlined in the Eligibility criteria 187 section below. The registered protocol, and this paper, follows the Preferred Reporting Items for 188 Systematic Reviews and Meta-Analysis (PRISMA) guidelines in conducting and reporting this 189

Based on these citation databases, a custom search strategy 196 was developed incorporating the search terms given below (Table 1). A preliminary search 197 revealed that a large fraction of the studies extracted by these search terms concerned vaccines 198 and antibodies, which are not relevant to the scope of this study. To exclude these studies, we 199 included the following NOT terms: antibodies; vaccine*; vaccination. Where possible, the search 200 was also limited by publication language (English) and date range to reflect the report 201 characteristics as highlighted in the eligibility criteria. The individual search strategies used for 202

Systematic review specialists from the Memorial University of Newfoundland libraries were 204 consulted to optimize the search strategy and ensure that it would capture all relevant studies. 205 The last search was run on 11

Table 1: List of Search Terms used in developing Search strategies 419 The mean half-lives of conjugated peptides are seen to increase overall as

There are, however, a few exceptions observed as in the cases of Fawaz et al. (38) and

In the McVicar, Rayavara & Carney study, TP508 was conjugated 423 with 4 different sizes of PEG, the smallest of which (PEG5k) exhibited a

When comparing 428 this study to others that involved PEGylated peptides, it was noted that the plasma half-life of the 429 peptides was shorter when the attached PEG moieties were smaller. This effect is observed in 430 both the Fu et al. (45) and McVicar, Rayavara & Carney (47) studies where the mean half-life of 431 the conjugated peptide increased as the size of PEG increased

Fig 2: The Effect Size of conjugation represented as Absolute Mean Differences of plasma half-life between

From the studies that were captured in our search, only 5 contained both experimentally 447 derived control values and standard deviations, which were included in our random effects meta-448 analysis model

Table 4: Meta-statistics calculated for the studies included in the meta-analysis

The weighted effect sizes (WES) of each individual study and the combined effect

High heterogeneity, however, is expected as we are 460 comparing effect sizes of studies that work with different therapeutic peptides, conjugates, 461 sample sizes, sexes, and drug doses. Moreover, the inter-study variance, or Tau-square (τ 2 ), was 462 calculated to be 19.54 for these studies. The square-root of τ 2 is an estimate of the standard 463 deviation of underlying effects across the studies analysed. Therefore, the larger τ 2 is, the higher 464 the underlying heterogeneity of the set of studies

Fig 3: Forest Plots detailing summary statistics from (A) all the meta-analysed peptides and (B) peptides that 469 use fatty acids as conjugates

The size of the 471 square is indicative of the weight assigned to the study. The diamond at the bottom indicates the combined effect 472 size and 95% confidence intervals. A vertical line through the vertices of the diamond reads the point estimate of the 473 combined effect whereas a horizontal line through the vertices indicates the 95% confidence interval. Forest Plot A 474 indicates very high heterogeneity (I 2 = 99.9 %) and is not statistically significant

477 478 A second Forest Plot was graphed to compare studies that used similar conjugates in an 479 attempt to minimize the heterogeneity observed when comparing the entire collection of peptides 480 (Fig 3b). Of the eligible studies

The high I 2 value in this case may be due to the 484 different peptide drugs and the different strains of rats (Sprague-Dawley rats and Wistar rats 485 respectively) used in the studies. As seen in Fig 3b, the 95% CI of the combined effect size 486 estimate does not cross the line of null effect indicating that the improvement in half life is 487 statistically significant. Additionally, the combined effect estimate is contained on the right side 488 of the line of null effect (favouring conjugation)

While there was more than one study that skewed the results (Fig 4), 498 it seems that Zorzi et al. (41) had the most impact on the combined effect size as seen by the 499 deviation recorded in Fig 4. This deviation may be attributed to the differences in sample size 500 and peptide used in the Zorzi et al. study. More significantly, this deviation could also be due to 501 the specifically synthesized acylated recombinant peptide conjugate that led to a larger effect 502 size (ES = 7.10; Table 3) as compared to the other studies we analysed (39). Zorzi et al. 503 describes this peptide-FA tag as an HSA-binding heptapeptide acylated with palmitic acid

The central thick line 508 indicates the overall effect as seen in Fig 3. The two vertical lines on either side indicates its 95% CI

We chose to assess inter-study risk of bias (RoB) 517 using the SYRCLE RoB tool (Fig 5). A breakdown of the RoB analysis for each individual study 518 is provided in Supplementary Table S3. RoB was analysed across several domains related to the 519 methods and reporting of the experiments in the studies. However, several studies included in 520 our SRMA did not adequately detail methodology of interest in pre-clinical trials such as details 521 on sequence generation, anonymization methods, and random outcome assessment

Of the studies that did provide 524 adequate detail, there were a few that scored high and low RoB in certain domains. The 525 reasoning for a high risk of bias score for studies captured in our meta-analysis are as follows. Fu 526 et al. (45) recorded high RoB in the 'Baseline Characteristics' domain as it only mentioned the 527 sex and weight of the animals. There was no mention of the animal's level of physical health

40) recorded high RoB in 'Incomplete Outcome Reporting' because of an 530 unexplained attrition in sample size reported in the results as compared to that reported in the 531 methods. Additionally, there was no explanation provided for the attrition recorded. All 5 studies 532 meta-analysed scored a majority of unsure and low RoB in the remaining domains

SYRCLE's Risk of Bias (RoB) domains were 536 used to assess risk of bias in the studied included in the SRMA. The modifications made to this template are noted in 537 the materials section. The breakdown of RoB analysis for each individual study is

The purpose of this systematic review and meta-analysis was to identify the various 543 peptide conjugate moieties currently under investigation, and which of them conferred the 544 greatest plasma half-life to peptide therapeutics. Of the conjugates included in this review, 545 glycosaminoglycans (HPN and CH) were the most effective in terms of increasing plasma half-546 life as measured by the absolute mean difference between conjugated vs unconjugated peptides 547 (Fig 2). Further, in the five eligible studies that were meta-analysed

Drug Carriers for the Delivery of Therapeutic Peptides

Therapeutic peptides: Historical perspectives, current development 599 trends, and future directions

Peptide chemistry 602 toolbox -Transforming natural peptides into peptide therapeutics. Bioorganic and 603 Medicinal Chemistry

Impact Story: Developing the Tools to Evaluate 607 Complex Drug Products: Peptides

Basics of Antibody 611 Phage Display Technology

Peptides and peptide conjugates: 613 Therapeutics on the upward path

Specificity in molecular design: A physical framework for 615 probing the determinants of binding specificity and promiscuity in a biological 616 environment

Half-Life Extension of 618 Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation

Recent Advances in Half-life 621 Extension Strategies for Therapeutic Peptides and Proteins. Current Pharmaceutical 622 Design

Peptide therapeutics: Current status and future directions

A review of lipidation in the 626 development of advanced protein and peptide therapeutics

Current strategies in 629 extending half-lives of therapeutic proteins

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make 632 Biobetters

Non-covalent albumin-binding ligands for extending the 634 circulating half-life of small biotherapeutics

Anti-PEG antibodies in the clinic: Current issues and 636 beyond PEGylation

Preferred reporting items for systematic 638 reviews and meta-analyses: The PRISMA statement

Pharmacokinetics of protein and peptide conjugates

HDL as a drug and nucleic acid 643 delivery vehicle

Reconstituted HDL: Drug 645 delivery platform for overcoming biological barriers to cancer therapy

Veritas Health Innovation. Covidence systematic review software

Available from: www.covidence.org 649 22. Cochrane Consumers and Communication La Trobe University

Data extraction template

Meta-analysis 652 of data from animal studies: A practical guide

Introduction to meta-analysis

Meta-Analysis Fixed effect vs. random effects [Internet

Measuring inconsistency in meta-659 analyses

Introduction to systematic review and meta-analysis. Korean Journal of 661 Anesthesiology

Instruments for Assessing Risk of Bias and Other 663

SYRCLE's risk of bias tool for animal studies. BMC Medical Research 667 Methodology

Gray literature: An important resource in systematic reviews

The 671 PRISMA statement for reporting systematic reviews and meta-analyses of studies that 672 evaluate health care interventions: explanation and elaboration

Prolonged half-life of 675 small-sized therapeutic protein using serum albumin-specific protein binder

Recombinant peptide production 678 platform coupled with site-specific albumin conjugation enables a convenient production 679 of long-acting therapeutic peptide

Glycosaminoglycan-Conjugated Insulin Derivatives Suitable for Once-Daily 682 Formulations

Glycosaminoglycan Conjugation for Improving the Duration of Therapeutic Action of 685 Glucagon-Like Peptide-1

687 Disposition of basal insulin peglispro compared with 20-kDa polyethylene glycol in rats 688 following a single intravenous or subcutaneous dose. Drug Metabolism and Disposition

691 Discovery and characterization of a potent interleukin-6 binding peptide with neutralizing 692 activity in Vivo

Phospholipid component 694 defines pharmacokinetic and pharmacodynamic properties of synthetic high-density 695 lipoproteins

A novel stearic acid-modified hirudin 698 peptidomimetic with improved pharmacokinetic properties and anticoagulant activity

Influence of route of 701 administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and 702 cholesterol mobilization

Acylated heptapeptide binds 704 albumin with high affinity and application as tag furnishes long-acting peptides

Sex as an important biological variable in biomedical research

Similar elimination rates of glucagon-like 709 peptide-1 in obese type 2 diabetic patients and healthy subjects

Chemical 712 conjugation of evans blue derivative: A strategy to develop long-acting therapeutics 713 through albumin binding

PEGylated leuprolide with 715 improved pharmacokinetic properties. Bioorganic and Medicinal Chemistry

Engineering of a 718 Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-719 Hormonal Treatment for Obesity

Radiomitigation and Tissue Repair Activity of 722

Systemically Administered Therapeutic Peptide TP508 Is Enhanced by PEGylation. 723 AAPS Journal

Myristic acid-modified thymopentin 725 for enhanced plasma stability and immune-modulating activity. International 726 Immunopharmacology

Lost in translation: the valley of death across preclinical and clinical divide -728 identification of problems and overcoming obstacles. Translational Medicine 729 Communications

Table S1: Systematic Search Strategy used for PubMed, Scopus, and SciFinder

Table S2: Characteristics of relevant studies captured in the systematic search

Breakdown of the Risk of Bias analysis for individual studies. 738 739 PRISMA checklist 740 741 Protocol: PROSPERO Protocol Registration 742 743 Data: Excel spreadsheet with all numerical data and statistical formulae